From Election to Coup The 2006 Campaign and its Aftermath

In May 2006 Fiji held its tenth general election since independence in 1970. In a country with an unenviable history of electoral trauma, the mood was apprehensive if not tense – not least because of controversial public statements against the incumbent Qarase government being made by the commander of Fiji’s military forces. Despite a record number of parties and candidates, the winners were the two big parties – the heavily church-backed SDL, the party of choice of the majority of indigenous Fijians; and the Fiji Labour Party, the party preferred by most Indo-Fijians. Although the result was ethnically polarised, for the first time in Fijian history the successful candidates came together to share power in a constitutionally ordained multiparty cabinet, with Laisenia Qarase retaining the prime ministership. But the fragile collaboration was short-lived. On 5 December 2006, Commodore Voreqe Bainimarama ordered a military takeover, declaring himself ‘President’, ousting the elected government and replacing it with an ‘interim’ government of his choice, and once again throwing Fiji into political turmoil. With contributions from ex-Vice President Ratu Joni Madraiwiwi, ousted Prime Minister Laesenia Qarase, leader of the Fiji Labour Party and now interim Minister for Finance Mahendra Chaudhry, and an impressive array of leading commentators on Fijian affairs, this book provides a comprehensive and penetrating analysis of the lead-up to, the outcome and the aftermath of Fiji’s historic 2006 election. Shedding light on the complex weave of traditional chiefly systems, race relations, economics, constitutionality, the military ethos and religion, From Election to Coup in Fiji is essential reading for anyone with an interest in Fiji, the South Pacific and the politics of divided societies

Holocene-Neogene volcanism in northeastern Australia: chronology and eruption history

Quaternary and late Neogene volcanism is widespread in northeastern Australia, producing at least 397 eruptions covering more than 20,000 km2, including at least 20 flows over 50 km long. Despite this abundance of young volcanism, before this study numerous eruptions had tentative ages or were undated, and the area requires a comprehensive evaluation of eruption patterns through time. To help address these issues we applied multi-collector ARGUS-V 40Ar/39Ar geochronology to determine the age of four of the younger extensive flows: Undara (160 km long, 189 ± 4/4 ka; 2σ, with full analytical/external uncertainties), Murronga (40 km long, 153 ± 5/5 ka), Toomba (120 km long, 21 ± 3/3 ka), and Kinrara (55 km long, 7 ± 2/2 ka). Verbal traditions of the Gugu Badhun Aboriginal people contain features that may potentially describe the eruption of Kinrara. If the traditions do record this eruption, they would have been passed down for 230 ± 70 generations – a period of time exceeding the earliest written historical records. To further examine north Queensland volcanism through time we compiled a database of 337 ages, including 179 previously unpublished K-Ar and radiocarbon results. The compiled ages demonstrate that volcanic activity has occurred without major time breaks since at least 9 Ma. The greatest frequency of eruptions occurred in the last 2 Ma, with an average recurrence interval of <10–22 ka between eruptions. Activity was at times likely more frequent than these calculations indicate, as the geochronologic dataset is incomplete, with undated eruptions, and intraplate volcanism is often episodic. The duration, frequency, and youthfulness of activity indicate that north Queensland volcanism should be considered as potentially still active, and there are now two confirmed areas of Holocene volcanism in eastern Australia – one at each end of the continent. More broadly, our data provides another example of 40Ar/39Ar geochronology applied to Holocene and latest Pleistocene mafic eruptions, further demonstrating that this method has the ability to examine eruptions and hazards at the youngest volcanoes on Earth

A biotechnological strategy for the valorization of cellulose through Levoglucosenone

Please click Download on the upper right corner to see the full description

A Review and update of the Health of the Nation Outcome Scales (HoNOS)

Summary Aims and method: The Health of the Nation Outcome Scales (HoNOS) and older adults version (HoNOS 65+) have been used widely for 20 years but their glossaries have not been revised to reflect clinicians’ experiences or changes in service delivery. The Royal College of Psychiatrists convened an international advisory board, with UK, Australian and New Zealand expertise, to identify desirable amendments. The aim was to improve rater experience by removing ambiguity and inconsistency in the glossary rather than more radical revision. Results Changes proposed to the HoNOS are reported. HoNOS65+ changes will be reported separately. Based on the views and experience of the countries involved a series of amendments were identified. Clinical implications While effective clinician training remains critically important, these revisions aim to improve intra- and inter-rater reliability and improve validity. Next steps will depend on feedback from HoNOS users. Reliability and validity testing will depend on funding. Declaration of interest None

The Dating of Kierkegaard's The Conflict between the Old and the New Soap-Cellars: A New Proposal

The Dating of Kierkegaard's The Conflict between the Old and the New Soap-Cellars: A New Proposa

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.

OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability